INCR.TA - InterCure Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILA
365.00
+74.20 (+25.52%)
At close: 3:49PM IDT
Stock chart is not supported by your current browser
Previous Close290.80
Open315.00
Bid365.00 x 7471200
Ask365.50 x 1676700
Day's Range301.90 - 365.00
52 Week Range185.30 - 1,208.00
Volume1,835,647
Avg. Volume598,879
Market Cap395.959M
Beta (5Y Monthly)-0.20
PE Ratio (TTM)2,134.50
EPS (TTM)0.17
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Cellect Biotechnology and Canndoc Ltd. to Enter Into Strategic Pharma Grade Cannabis Commercial Deal for Reduction in Opioid Usage
    PR Newswire

    Cellect Biotechnology and Canndoc Ltd. to Enter Into Strategic Pharma Grade Cannabis Commercial Deal for Reduction in Opioid Usage

    Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology that enables the functional selection of stem cells, today announced that its Board of Directors has approved, and the company has entered, subject to definitive agreements, into a commercial binding Letter Of Intent (LOI) with Canndoc Ltd, a leading pharma grade medical cannabis pioneer, a wholly owned subsidiary of publicly-traded Intercure Ltd. (TASE: INCR).

  • INTERCURE: CANNDOC Initiates Phase 3 Clinical Trial Evaluating Pharma Grade Medicinal Cannabis (CANNDOC T1/C20) For Children With Autism Spectrum Disorder
    PR Newswire

    INTERCURE: CANNDOC Initiates Phase 3 Clinical Trial Evaluating Pharma Grade Medicinal Cannabis (CANNDOC T1/C20) For Children With Autism Spectrum Disorder

    HERZLIYA, Israel, Nov. 21, 2019 /PRNewswire/ -- Israeli medical cannabis company InterCure Ltd. (TASE: INCR) announced that its wholly-owned subsidiary Canndoc initiated a phase 3 clinical trial with the Shamir Medical Center (Assaf HaRofeh) for the treatment of children with autism spectrum disorder. The program will be led by Dr. Orit Stoller, a pediatric neurologist at the Autism Center at Shamir (Assaf HaRofeh), and Prof. Mati Berkovitch, Head of the Clinical Pharmacology Unit at the Shamir Medical Center (Assaf HaRofeh),  validating the safety and efficacy of Canndoc's GMP pharma grade cannabis product T1/C20 for children with autism spectrum disorder.

  • PR Newswire

    INTERCURE: CANNDOC signs strategic distribution agreement with S.L.E. of TEVA Pharmaceuticals

    HERZLIYA, Israel, Sept. 13, 2019 /PRNewswire/ -- InterCure (INCR.TA), announced that subsidiary Canndoc has entered into a strategic distribution agreement with Salomon, Levin, Elstein (S.L.E.,) which is owned by Teva Pharmaceuticals Industries (NYSE: and TASE: TEVA). Under terms of the agreement, S.L.E. will distribute Canndoc's GMP products to pharma clients, including hospitals, health maintenance organizations (HMOs) and all pharmacies in Israel, including pharmacy chains. In the future, as regulatory approvals allow, S.L.E. will provide logistics capability for exporting Canndoc's products to countries that support regulations for the sale and distribution of cannabis products for medical use.